Compare Immunovant Inc. Common Stock (IMVT) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Northrop Grumman Corporation — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Northrop Grumman Corporation trades at $480.72 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 11× Immunovant Inc. Common Stock's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Northrop Grumman Corporation for 81 Days on average.
| IMVT | NOC | |
|---|---|---|
Market Cap | $6.25B | $68.83B |
Volume | 1,755,411 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $44.96 | $768.02 |
52-Week Low | $17.03 | $473.46 |
Typical Hold Time | 1 Days | 81 Days |
Enterprise Value | $5.35B | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Northrop Grumman (NOC) trades at $484.48, up 2.33% on the day, but technical indicators signal a bearish trend. The company demonstrates strong fundamentals with consistent earnings beats, a net income margin of 10.48%, and a robust backlog. Recent news highlights a competitive setback with Boeing winning a major Navy contract, though the company maintains solid defense sector positioning.
The outlook is mixed; strong profitability and analyst buy ratings support upside to a $600.62 consensus target, but near-term technical pressure and contract loss risks pose challenges. Revenue growth and dividend stability offer investor appeal, though sector volatility and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
